Seattle Translational Tumor Research (STTR) bring together experts across 16 blood, lymphatic and solid tumors — bladder, brain, breast, colorectal, head & neck, leukemia, liver, lung, lymphoma, myelodysplastic/myeloproliferative disease, myeloma, ovary, pancreas, prostate, rare cancers and skin.
STTR is a transformative movement creating a strong sense of community among Seattle’s cancer investigators. Located in Seattle, the STTR group is comprised of investigators from three leading Northwest institutions — Fred Hutch Cancer Center, UW Medicine, and Seattle Children’s.
Our vision is an environment tailored to researchers and clinicians which allows them to accelerate scientific discoveries and translate them into cures for patients, both regionally and globally. With the support from our philanthropic partners, we are poised to make major research advances that will significantly improve patient quality of life and survival.
Our Approach
STTR's multidisciplinary, multi-institutional team includes experts in mathematical modeling, computer simulation, visualization, bioengineering, big data mining, cancer biology, precision oncology, population science and the best clinicians in the field.
We are using state-of-the-art technology and scientific innovation to catalyze translational research and more rapidly turn laboratory findings, populations studies and clinical insights into clinical practice and population-level recommendations. The goals of the program are to enhance the understanding of cancer biology and therapeutic responses and to identify personalized treatments that improve patient outcomes.
STTR fosters and promotes intellectual participation and collaboration with lectures, retreats, working groups, protocol development, biospecimen collection and utilization, joint publications and grants.
We believe there are many promising cancer therapies on the horizon. Combining our expertise will enable the design and delivery of the new therapies more efficiently and quickly to patients.
